Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.36|
|52 Week High||AU$0.14|
|52 Week Low||AU$0.50|
|1 Month Change||-1.35%|
|3 Month Change||78.05%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||87.18%|
Recent News & Updates
Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|HXL||AU Biotechs||AU Market|
Return vs Industry: Insufficient data to determine how HXL performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how HXL performed against the Australian Market.
Stable Share Price: HXL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: HXL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
|1997||n/a||Michael D. Aldridge||https://www.hexima.com.au|
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company’s lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. The company was incorporated in 1997 and is headquartered in Melbourne, Australia.
Hexima Fundamentals Summary
|HXL fundamental statistics|
Is HXL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HXL income statement (TTM)|
|Cost of Revenue||AU$208.58k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.053|
|Net Profit Margin||-168.39%|
How did HXL perform over the long term?See historical performance and comparison
Is Hexima undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HXL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HXL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HXL is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: HXL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HXL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HXL is overvalued based on its PB Ratio (15.7x) compared to the AU Biotechs industry average (4.9x).
How is Hexima forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hexima has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Hexima performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HXL is currently unprofitable.
Growing Profit Margin: HXL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HXL is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare HXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: HXL has a negative Return on Equity (-225.69%), as it is currently unprofitable.
How is Hexima's financial position?
Financial Position Analysis
Short Term Liabilities: HXL's short term assets (A$7.4M) exceed its short term liabilities (A$3.9M).
Long Term Liabilities: HXL's short term assets (A$7.4M) exceed its long term liabilities (A$1.6M).
Debt to Equity History and Analysis
Debt Level: HXL's debt to equity ratio (1.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if HXL's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HXL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HXL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.7% each year
What is Hexima current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HXL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HXL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HXL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael D. Aldridge (54 yo)
Mr. Michael D. A. Aldridge, B.Sc (Hons)., MApFin, serves as Managing Director and Chief Executive Officer at Hexima Limited since October 1, 2020 and serves as its Executive Director since May 21, 2019. He...
CEO Compensation Analysis
Compensation vs Market: Michael D.'s total compensation ($USD650.39K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Michael D.'s compensation has increased whilst the company is unprofitable.
Experienced Management: HXL's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: HXL's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: HXL only recently listed within the past 12 months.
Hexima Limited's employee growth, exchange listings and data sources
- Name: Hexima Limited
- Ticker: HXL
- Exchange: ASX
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$47.763m
- Shares outstanding: 130.86m
- Website: https://www.hexima.com.au
- Hexima Limited
- La Trobe Institute for Molecular Science
- Level 4,LIMS 2
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:28|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.